Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder

NCT05243329 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Treatment Resistant Disorders
Post Traumatic Stress Disorder

Interventions

DRUG: Psilocybin

Sponsor

Halucenex Life Sciences Inc.

Collaborators

[object Object]